Feasibililty of Azacitidine As Bridge to Allogeneic

Feasibililty of Azacitidine As Bridge to Allogeneic Stem Cell
Transplantation in Patients with Higher-Risk MDS or LowBlast Count AML: Results of the BMT-AZA Multicenter
Prospective Study
by Maria Teresa Voso, Giuseppe Leone, Alfonso Piciocchi, Luana Fianchi, Paolo Di
Bartolomeo, Anna Candoni, Marianna Criscuolo, Arianna Masciulli, Elisa Cerqui,
Alfredo Molteni, Carlo Finelli, Matteo Parma, Flavia Rivellini, Nicola Cascavilla,
Francesco Spina, Agostino Cortelezzi, Flavia Salvi, Mauro Montanari, Emilio Paolo
Alessandrino, Alessandro Rambaldi, and Simona Sica
Blood
Volume 126(23):66-66
December 3, 2015
©2015 by American Society of Hematology
Overall survival (n=93 pts).
Maria Teresa Voso et al. Blood 2015;126:66
©2015 by American Society of Hematology
Survival according to disease status at response assessment after a median of 4.5 azacitidine
cycles (n=77 evaluable pts).
Maria Teresa Voso et al. Blood 2015;126:66
©2015 by American Society of Hematology
Maria Teresa Voso et al. Blood 2015;126:66
©2015 by American Society of Hematology